Categoría: Stem Cell Research
-
Business is Booming as Pfizer Targets the Aging Processs With New Adult Stem Cell Research
As yet another indication of the economic maturation of an industry, the pharmaceutical giant Pfizer is now developing anti-aging stem cell products.
-
An Adult Stem Cell Company Wins Award for Innovation
The biotech company Mesoblast Ltd., specializing in regenerative medicine, is awarded a prestigious award for its adult stem cell technology.
-
FDA Grants Clearance for the First Clinical Study With Placental Stem Cells
Celgene Cellular Therapeutics receives FDA authorization to commence the first clinical trials ever to be conducted in the U.S. with adult stem cells derived from placental blood.
-
Opexa to Present Data on its Cellular Therapies for Autoimmune Diseases
Opexa Therapeutics is scheduled to present an overview of its T-cell and adult stem cell therapies for autoimmune diseases at an annual health care conference.
-
Genzyme and Osiris Form Adult Stem Cell Mega-Partnership
In one of the largest business arrangements ever made, Osiris and Genzyme agree upon a major adult stem cell collaboration.
-
The Potentiation of Mesenchymal Stem Cells Improves Cardiac Regeneration
Scientists increase the efficacy of mesenchymal stem cells through a process of molecular «supercharging» for the therapeutic regeneration of heart tissue following myocardial infarction.
-
Neuralstem Licenses Technology for Spinal Cord Treatment
The stem cell company Neuralstem, Inc., announces the licensing of patents for the delivery of targeted spinal cord therapeutics.
-
Pfizer Expands Into Stem Cell Research
Lured by the promise of financial profit, the pharmaceutical giant Pfizer joins the stem cell community.
-
Pluristem’s Adult Stem Cell Product Shows Promise as Therapy for Multiple Sclerosis
The biotech company Pluristem Therapeutics has developed an adult stem cell product for the prevention of clinical symptoms of multiple sclerosis.
-
Two Leading Biotech Companies Collaborate on a Department of Defense Contract for Adult Stem Cell Applications in Warfare
In an effort to develop adult stem cell therapies that are specifically targeted to counteracting the biological dangers of nuclear warfare, the U.S. Deparment of Defense has awarded a $224.7 million contract to an Osiris-Genzyme partnership.